Dual neutralisation of interleukin IL17s appears to be more effective than current IL17A inhibitors against psoriatic arthritis but further work including direct comparison is needed. While the current two IL17A inhibitors secukinumab and ixekizumab have shown good results in psoriatic arthritis, treatment with bimekizumab targeting both IL17A and IL17F appears to be associated with clinically ...
Next generation dual IL17 inhibitor shows promise against psoriasis
By Mardi Chapman
14 Feb 2020